Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems

Abstract Cancer remains the second leading cause of death globally, driving the need for innovative therapies. Among natural compounds, maytansinoids have shown significant promise, contributing to nearly 25% of recently approved anticancer drugs. Despite their potential, early clinical trials faced...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Matteo Perra, Ines Castangia, Matteo Aroffu, Federica Fulgheri, Rita Abi-Rached, Maria Letizia Manca, Hernán Cortés, María Luisa Del Prado-Audelo, Carla Nomura-Contreras, Alejandra Romero-Montero, Dietrich Büsselberg, Gerardo Leyva-Gómez, Javad Sharifi-Rad, Daniela Calina
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Springer 2025-01-01
coleção:	Discover Oncology
Assuntos:	Maytansine Maytansinoid-based therapies Antibody-maytansinoid conjugates Natural compounds Anticancer studies Microtubules polymerization inhibitors
Acesso em linha:	https://doi.org/10.1007/s12672-025-01820-z
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!